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Abstract 
Background: Transient receptor potential melastatin 3 (TRPM3) cation channels are ubiquitously expressed by 
multiple cells and have an important regulatory role in calcium‑dependent cell signalling to help maintain cellular 
homeostasis. TRPM3 protein expression has yet to be determined on Natural Killer (NK) cells and B lymphocytes. Mul‑
tiple single nucleotide polymorphisms have been reported in TRPM3 genes from isolated peripheral blood mononu‑
clear cells, NK and B cells in Chronic fatigue syndrome/Myalgic encephalomyelitis (CFS/ME) patients and have been 
proposed to correlate with illness presentation. The object of the study was to assess TRPM3 surface expression on NK 
and B lymphocytes from healthy controls, followed by a comparative investigation examining TRPM3 surface expres‑
sion, and cytoplasmic and mitochondrial calcium influx in CD19+ B cells, CD56bright and CD56dim cell populations from 
CFS/ME patients.
Results: TRPM3 cell surface expression was identified for NK and B lymphocytes in healthy controls (CD56bright TRPM3 
35.72 % ± 7.37; CD56dim 5.74 % ± 2.00; B lymphocytes 2.05 % ± 0.19, respectively). There was a significant reduction 
of TRPM3 surface expression on CD19+ B cells (1.56 ± 0.191) and CD56bright NK cells (17.37 % ± 5.34) in CFS/ME com‑
pared with healthy controls. Anti‑CD21 and anti‑IgM conjugated biotin was cross‑linked with streptavidin,and subse‑
quently treatment with thapsigargin. This showed a significant reduction in cytoplasmic calcium ion concentration 
in CD19+ B lymphocytes. CD56bright NK cells also had a significant decrease in cytoplasmic calcium in the presence of 
2‑APB and thapsigargin in CFS/ME patients.
Conclusions: The results from this preliminary investigation identify, for the first time, TRPM3 surface expression on 
both NK and B lymphocytes in healthy controls. We also report for the first time, significant reduction in TRPM3 cell 
surface expression in NK and B lymphocytes, as well as decreased intracellular calcium within specific conditions in 
CFS/ME patients. This warrants further examination of these pathways to elucidate whether TRPM3 and impaired 
calcium mobilisation has a role in CFS/ME.
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Background
Mammalian Transient receptor potential ion channels 
(TRPs) are comprised of six main groups including the 
TRPA (ankyrin), TRPC (canonical), TRPM (melasta-
tin), TRPML (mucolipin), TRPP (polycystin) and TRPV 
(vanilloid) [1]. These have been found to have different 
biological functions, activation mechanisms and differen-
tial expression on tissues throughout the body [2]. TRPs 
are extensively expressed on almost all cells and their 
dysregulation has been associated with pathological con-
ditions and diseases such as cancer, glomerulosclerosis, 
pain syndrome, Olmsted syndrome, mucolipidoses, and 
polycystic kidney disease [3–5].
TRPs are activated following fluctuations or devia-
tions in the cellular environment, including pathogens, 
temperature, pressure, chemicals, oxidation and reduc-
tion, toxins, osmolarity, and pH [6, 7]. TRPs are calcium 
(Ca2+) permeable cation channels that act as an excita-
tory signal when open to induce depolarisation of the 
cell and allow Ca2+ influx. Ca2+ plays a role in intracel-
lular signalling pathways, contributing to a number of 
cellular processes, for example cell division, apoptosis 
and transcriptional events [8]. TRPM3 protein expres-
sion has been identified on pancreatic β cells, [9] as well 
as on cells in the central nervous system and the eye [2]. 
Chronic fatigue syndrome, also referred to as Myalgic 
encephalomyelitis (CFS/ME) (is a disorder marked by 
unexplained, debilitating fatigue accompanied by a range 
of symptoms relating to multiple physiologies [12]. CFS/
ME patients may have reactions to a number of environ-
mental and biological factors [13]. TRP channels may be 
targeted during inflammatory reactions as they are easily 
activated in the presence of irritants, inflammatory prod-
ucts, and xenobiotic toxins. Symptoms relating to sen-
sitivity to toxins and irritants have also been associated 
with CFS/ME [14], however the causes of these sensitivi-
ties have not been fully investigated.
Immunological dysfunction is commonly reported in 
CFS/ME. A significant reduction in NK cytotoxic activ-
ity is a consistent finding in CFS/ME patients compared 
with healthy controls [15–26]. Furthermore, a significant 
increase in CD20+CD5+ B cells and CD19+IgM+ B cells 
has been reported in CFS/ME patients compare with 
healthy controls [27–31]. Atypical SNPs of TRP genes, 
particularly SNPs in TRPM3 from peripheral blood 
mononuclear cells, NK and B cells have been recently 
reported in CFS/ME groups compared with healthy 
controls [10, 11, 32]. Thus, the first aim of this prelimi-
nary investigation was to identify TRPM3 surface pro-
tein expression on NK and B lymphocytes from healthy 
controls, using flow cytometric protocols. To date, there 
has been no previous evidence of this expression. Fur-
thermore, protocols used to identify TRP receptors on 
specific cell subsets are based on spectroscopy and crys-
tallography methods. The second aim of this study was to 
conduct a comparative assessment between CFS/ME and 
healthy controls for TRPM3 surface protein expression 
and changes in intracellular calcium influx in NK and B 
lymphocytes. Perturbations of TRPM3 expression and 
consequent changes in intracellular calcium influx could 
provide further knowledge as to the possibility of TRPM3 
contributing to the pathogenesis of CFS/ME.
Methods
Subjects
This study consisted of 17 CFS/ME patients that were 
aged matched with 19 healthy controls (Table  1). Of 
the 17 CFS/ME patients (age =  48.68 ±  1.06  years), 14 
(82  %) were females and 3 (18  %) were males. The 19 
healthy controls (age  =  46.48  ±  1.22  years) comprised 
13 (68 %) females and 6 (32 %) males. CFS/ME patients 
were defined according to the Fukuda criteria, which 
required persistent, ongoing fatigue for at least 6 months 
accompanied by at least 4 of the following: post-exer-
tional malaise, impaired short term memory or con-
centration, unrefreshed sleep, headaches, sore throat, 
tender lymph nodes, muscle pain, and joint pain [12]. 
The average duration of illness of this group was 8.4 years 
and reported no alternative disease or illness that would 
explain the onset of their symptoms. Any patients on 
potential immune modulating medication were excluded 
from this study. Healthy controls did not meet any CFS/
ME criteria. All participants in this study were of Cauca-
sian decent and residents of Australia at the time of blood 
collection. Exclusion criteria for all participants involved 
in this study were those who were smokers, pregnant or 
breastfeeding.
80  ml of whole blood was collected from all par-
ticipants into EDTA blood tubes. Written consent was 
obtained from all participants prior to sample collec-
tion. Pathology testing parameters (full blood count, 
electrolytes, high sensitive C reactive protein and eryth-
rocyte sedimentation rate) were performed on all par-
ticipants. No significant differences in these pathology 
testing parameters were identified between groups (data 
not shown). This investigation was conducted under the 
Griffith University Ethics reference number (HREC/15/
QGC/63).
Peripheral blood mononuclear cells preparations
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from 40  ml EDTA blood after obtaining partici-
pants’ written consent. PBMCs were isolated using Ficoll 
density gradient centrifugation (Life technologies) as 
previously described [22]. PBMCs were counted using 
Trypan blue and concentration was adjusted to 1 × 107 
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cells in 100  μl in Dulbecco’s phosphate-buffered saline 
(DPBS) with Ca2+ and magnesium (Life technologies) for 
all assays.
TRPM3 immunophenotyping assay
Due to the constitutive active property of TRPM3 pro-
tein and readily available anti-TRPM3 antibody, this 
study utilised anti-TRPM3 antibody to measure protein 
expression as the antibody binds to the extracellular sur-
face of the protein structure. Initially, PBMCs were incu-
bated in 20 μl of FCR blocking reagent (Miltenyi Biotec) 
for 10 min at room temperature and washed with phos-
phate buffer saline (PBS) prior to centrifuge at 400g for 
5 min. Supernatant was removed and incubated with pri-
mary fluorochrome labelled antibodies (CD19-BV421, 
CD3-PerCP, CD56-BV421 and CD16-APC Cy7, purchase 
from BD Bioscience) for 30 min at room temperature in 
the dark. Labelled cells were washed and incubated with 
10  μg final concentration of goat anti-human TRPM3 
antibody for 30  min. This was followed by a wash and 
resuspension in a final concentration of 5  % (v/v) of 
Bovine Serum Albumin (Sigma) for 30  min. Cells were 
washed again and incubated with 5 μg final concentration 
of donkey anti-goat IgG FITC (Santa Scruz) for 30 min. 
Cells were washed and resuspended in 200  μl of stain-
ing buffer (BD Bioscience) and acquired at 50,000 events 
using LSRFortessa X-20 (BD Bioscience).
LSR Fortessa X‑20 flow cytometry analysis
Lymphocyte populations were identified using forward 
scatter and side scatter (FSC, SSC) dot plots. Exclusions 
were CD3+ cells and only CD3− lymphocytes were fur-
ther used to characterised B lymphocytes and NK cell 
subset populations using CD19, CD56 and CD16 as pre-
viously described [22, 33]. Total B cells were identified 
as CD19+, whereas NK cell subsets were characterised 
using the expression of CD56BrightCD16Dim/− NK cells, 
CD56DimCD16Bright/+ NK cells and CD56−CD16+ NK 
cells (Fig.  1). TRPM3 expression was measured as per-
centage of parent cells (%) and mean fluorescence inten-
sity (MFI) (Additional file 1: Table S1). LSRFotessa X-20 
flow cytometry was utilised for sequential determina-
tion of cytoplasmic calcium [Ca2+]C and mitochondrial 
[Ca2+]M, to help compare cytoplasmic or mitochondrial 
Ca2+ influx kinetics in B lymphocytes and NK cells. 
Characterising kinetic measurements using median flo-
rescence of Fura-AM or Rhod-2 AM dye were used and 
smoothing curve method was applied to measure the 
area under the curve (AUC).
Cytoplasmic calcium influx assay
Following phenotypic staining, the cells were incu-
bated with 0.5  ml staining buffer that contained 0.02  % 
Pluronic® F-127 and 1  μM Fura-red AM or Rhod-2 
AM for 30  min in the incubator at 37  °C. Stained cells 
were washed with DPBS without calcium and magne-
sium. Fura AM stained cells were stimulated after 30  s 
of flow cytometric acquisition in the presence of a final 
concentration of 1.4  μg streptavidin, 714  ng ionomycin, 
50  μg 2-APB or 14  μg thapsigargin. Data was recorded 
over 4  min. Rhod-2 AM stain cells were incubated for 
a further 12  h, prior to acquisition. Unstimulated cells 
were used as a baseline when assessing the stimulation 
response’s AUC.
Thapsigargin is a potent inhibitor for Calcium-ATPase 
receptors and raises cytoplasmic calcium concentration 
by inhibiting the ability for the cells to pump calcium into 
the endoplasmic reticulum (ER) [34]. 50 ug 2-aminoeth-
oxydiphenyl borate (2-APB) was used given its inhibition 
of ER and IP3R as previously described [35]. NK receptors 
(NG2DA and NKp46) were cross-linked [36] to ensure 
co-stimulation of human NK cells to measure calcium 
influx. CD19 and CD21 (complement receptor CR2) on 
B cells are responsible for activating the Immunoglobulin 
M (IgM) receptor and the three proteins together make 
the B cell receptor complex. This complex was then sta-
bilised by streptavidin-mediated cross-linking to induce 
permanent calcium influx and enhance activation of 
CD19+ B cells [37].
Statistical data analyses
Statistical analyses were performed using IBM SPSS 
Statistics version 22 software (SPSS, Chicago, USA). 
Significance was tested by MANOVA and reported at 
the P  <  0.05 level between CFS/ME and healthy control 
groups for parameters including TRPM3 protein expres-
sion, and calcium influx in B lymphocytes and NK cells. 
Data are given as mean ± SEM. Flowjo was employed to 
analyse FCS files extracted from FACSDiva 8 software 
(BD Bioscience). Post Hoc test was further performed to 
determine specifically where the significance was between 
healthy controls and CFS/ME. The Levene test was used 
to analyse homogeneity of variance between groups.
Results
Subject characteristics
There was no significant difference in age between 
healthy controls (n  =  19, 48.32  ±  2.71) and CFS/ME 
patients (n = 17, 51.24 ± 2.14)
Identification of TRPM3 on Natural Killer cells and B 
lymphocytes
The fluorescence of fluorescein isothiocyanate con-
jugated (FTIC) secondary antibody was employed to 
quantitatively measure TRPM3 surface protein expres-
sion. Forward and side scatter dot plots were utilised 
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to identified lymphocyte population prior to gating 
CD56Bright NK cells (CD3−CD56BrightCD16−), CD56Dim 
NK cells (CD3−CD56dimCD16+) and total B cells 
(CD3−CD19+) (Fig. 1). TRPM3+ NK cell subsets (Addi-
tional file  2: Figure  1) and TRPM3+ B cells (Additional 
file 3: Figure 2) were further identified for CFS/ME and 
healthy controls.
Comparative assessment of TRPM3 on Natural Killer cells 
and B lymphocytes between healthy controls and CFS/ME 
patients
CD56Bright NK cells showed significantly decreased 
TRPM3 expression (17.37  ±  5.34  %) in CFS/ME com-
pared with healthy controls (35.72  ±  7.38  %) (Fig.  2a). 
Similarly, CD19+ cells demonstrated significantly 
decreased TRPM3 expression in CFS/ME (1.56 ±  SEM 
0.191  %) compared with healthy controls (2.06  ±  SEM 
0.16 %) (Fig. 2b). CD56Dim cells showed no significant dif-
ference between groups (Fig. 2a).
Cytoplasmic and mitochondrial calcium influx
Fura-2 AM and Rhod-2 AM exhibit an increase in fluo-
rescence upon binding to cytoplasmic and mitochon-
drial calcium ions. Changes in mitochondrial calcium 
concentration in the presence of stimulants showed 
no significance. CFS/ME patients showed significantly 
reduced cytoplasmic calcium ion concentration in 
CD19+ B cells during cross-linking of CD21 and IgM 
receptor (P < 0.01) (Fig. 3). CD56bright NK cells demon-
strated a significantly decreased cytoplasmic calcium 
influx in the presence of 50 μg 2-APB and 14 μg thapsi-
gargin (P < 0.05)(Fig. 4).
Fig. 1 Immunophenotype of TRPM3 channel surface expression on B and NK cells by flow cytometry. Total B cells were identified using Anti‑CD19. 
NK cells were characterised using the expression of CD56BrightCD16Dim/− NK cells, CD56DimCD16Bright/+ NK cells and CD56−CD16+ NK cells, followed 
by, identification of TRPM3 surface expression
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Discussion
The present paper reports, for the first time, the identi-
fication of TRPM3 surface expression on NK cells and B 
lymphocytes in CFS/ME patients as well as healthy con-
trols. Further, diminished expression of TRPM3 surface 
expression was found on B lymphocytes and NK cells in 
CFS/ME patients compared with healthy controls. We 
also report, for the first time, a significant reduction in 
cytoplasmic calcium ion concentration in CD19+ B lym-
phocytes during cross-linking between anti-CD21 and 
anti-IgM following treatment with stepadividin or thap-
sigargin in CFS/ME patients. CD56bright NK cells also had 
a significant decrease in cytoplasmic calcium in the pres-
ence of 2-APB and thapsigargin in CFS/ME patients.
Investigation of TRP ion channels expression on lym-
phocytes has been very limited due to the difficulties of 
methodology as TRP channels are in relatively low abun-
dance and there is limited availability of specific and 
high-affinity antibodies. Other methods of identifica-
tion of TRP include molecular genetics by assessing TRP 
mRNA expression or isolation of protein from plasma 
membrane. Also, investigations of TRP ion channel func-
tions and their roles in disease states have been reported 
through voltage clamping methodology or in  vitro cell 
lines. Knock-out animal models have also been reported 
to study TRP ion channels (see review: [38]). TRPM3 has 
been reported to be expressed on a wide variety of tissues, 
Fig. 2 TRPM3 expression (%) on B lymphocytes and NK cells gated 
from HC and CFS/ME peripheral mononuclear cells. a NK cells subsets 
were charactered as CD56Bright NK cells and CD56Dim NK cells. Identi‑
fication of TRPM3 surface expression on the NK cell subsets was ana‑
lysed using indirect flow cytometry. b B cells were characterised as 
total B cells (CD3−CD19+) and indirect flow cytometry was employed 
to identify TRPM3 surface expression on B cells. Histograms report 
the means ± SEM. Asterisk denotes P < 0.05. HC healthy controls, CFS 
Chronic fatigue syndrome
Fig. 3 Fura‑AM cytoplasmic calcium influx in CD19 + B cells. Calcium 
influx response curve reported as area under the curve was measure 
during Anti‑IgM and anti‑CD21 conjugated biotins were cross‑linked 
with streptavidin or in the presence of ionomycin, 2‑APB or thapsigar‑
gin. Histograms report the means ± SEM. Asterisk denotes statistically 
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Fig. 4 Fura‑AM cytoplasmic calcium influx response during 
CD56Bright NK cell receptors, Anti‑CD314 and anti‑CD335 conjugated 
biotins were cross‑linked with streptavidin or in the presence of iono‑
mycin, 2‑APB or thapsigargin. Histograms report the means ± SEM. 
Asterisk denotes statistically significance at P < 0.05
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such as kidneys, eyes, sensory neurons of the dorsal root 
ganglia and the β islet cells of the pancreases [2]. Only 
TRPM4, TRPM5, TRPM2 and TRPM7 surface expres-
sion have been reported on B cells, bone marrow cells, 
splenic cells, lymph node B cells and T and mast cells 
[39]. However, no previous investigation has reported 
TRPM3 on B lymphocytes or NK cells. Our novel find-
ings suggest TRPM3 on B lymphocytes and NK cells may 
also be involved in calcium-mediated roles, such as those 
seen with other TRP family members. These calcium-
mediated TRP functions contribute to a number of cel-
lular processes and cellular functions. These processes 
include regulating enzymatic function and transcription 
factors, lymphocyte proliferation and differentiation of 
naïve cells into effector and memory cells as well as the 
production of cytokines and chemokines (see review [8]). 
TRPM3 alone or in conjunction with TRPC members, 
members of the TRPV1 family, together with muscarinic 
M3 receptors [40] and calcium release activated calcium 
(CRAC) channels [41] may need to be considered for cal-
cium intracellular-mediated roles.
Our preliminary research findings report a significant 
reduction in TRPM3 surface expression for B lympho-
cytes and CD56Bright cells from CFS/ME patients com-
pared with healthy controls. Our group has recently 
reported significant associations of SNPs, predominately 
in TRPM3 genes, from NK and B lymphocytes in CFS/
ME patients compared with healthy controls [10, 11, 
32]. The significant reduction in TRPM3 surface pro-
tein expression in conjunction with a significant reduc-
tion in Ca2+ influx from CD56bright NK cells suggests 
important functional implications. When Ca2+ influx is 
prevented or reduced an immunological synapse is not 
formed [42, 43]. A rise or pulsatile influx in intracellular 
Ca2+ is required in cells, such as Natural Killer cells and 
cytotoxic lymphocytes to initiate cell function, such as 
the cell lysis of a target infected cell, as well as formation 
of mitotic spindles for cytoskeleton movement to facili-
tate the secretory vesicles to fuse with the plasma mem-
brane to ultimately form the immune synapse. Moreover, 
the production of lytic granules for targeting and killing 
infected cells is also dependent on Ca2+ [44].
Treatment with streptavidin cross-linked with NKD2A 
and NKp46, which are Ca2+ dependent, showed no sig-
nificant reduction for cytoplasmic calcium in CD56Bright 
NK cells. In contrast, treatment with thapsigargin or 
2-APB, suggests impairment of Ca2+ influx and storage. 
Treatment with 2-APB, which is both non-selective for 
TRPM3 [45] and an IP3R antagonist [35] showed a sig-
nificant difference in intracellular Ca2+. Treatment with 
thapsigargin showed a significant reduction in Ca2+ in 
the CFS/ME group compared with the healthy control 
group, suggesting Ca2+ stores may be a consequence of 
reduced Ca2+ influx into the cell, ultimately lowering 
the function and intracellular signalling capability of the 
cell. Recent research has identified that CD56bright NK 
cells are very likely precursor cells of the CD56dim sub-
set. CD56dim NK cells have been shown to have shorter 
telomeres than CD56bright NK cells from peripheral 
blood, suggesting CD56bright cells are not as mature as 
CD56dim [46]. Additionally, purified CD56bright CD16− 
NK cells have been shown to differentiate into CD56dim 
cells that have the characteristic phenotypic and func-
tional features of peripheral blood CD56dim NK cells [47]. 
CD56bright NK cells constitutively express the high- and 
intermediate-affinity IL-2 receptors and expand in  vitro 
and in vivo in response to low (picomolar) doses of IL-2 
[48, 49] and after activation with IL-2 or IL-12, CD56bright 
cells exhibit similar or enhanced cytotoxicity against NK 
targets compared with CD56dim cells [50]. We and others 
have shown significant reductions in CD56bright NK cells 
in CFS/ME patients, significant reductions in lytic func-
tion of CD56bright NK cells as well as significantly reduced 
lytic granules [16, 18, 26, 51] in CFS/ME patients.
Importantly, cross linking anti-IgM and anti-CD21 
initiates a calcium-dependent pathway through trans-
membrane proteins, most notably Igα (CD79a) and Igβ 
(CD79b). B cell linker protein (BLNK) binds to tyrosine 
of Igα via the intracellular mechanism of crosslinking 
Igα and Igβ cytoplasmic tails and phosphorylation of the 
immunoreceptor tyrosine-based activation motif (ITAM) 
tyrosines which occurs by Src-family tyrosine kinases 
(SFTKs) and/or Syk, ultimately leading to calcium influx 
and protein kinase C (PKC) activation [52]. In the present 
study, B lymphocytes treated with streptavidin showed 
a significant reduction of intracellular Ca2+. In contrast, 
treatment with 2-APB showed no significant reduction 
in intracellular Ca2+. However, treatment with thapsigar-
gin showed a significant difference in intracellular Ca2+. 
One rationale for this outcome may be due to calcium 
signalling by other TRP families identified, for example 
TRPM4, TRPM5 and TRPM2 that have been identified 
on B cells, bone marrow cells and lymph node B cells. It is 
feasible these other TRP subfamilies [39, 53], may play a 
role in intracellular Ca2+ influx and storage. Interestingly, 
muscarinic acetylcholine receptors have been found to 
inhibit TRPM3 via the action of phospholipase C [40]. 
Such interaction may provide additional complexity to 
Ca2+ cell signalling as we have recently reported a signifi-
cant association of SNPs in genes of muscarinic acetyl-
choline receptors M3 from the same cohort of CFS/ME 
patients who had significant association of SNPs in their 
TRPM3 genes from peripheral blood mononuclear cells 
[54]. Future investigations comparing cell subsets that do 
not express TRPM3 need to be explored. Additionally, 
pathways that potentially influence calcium influx may 
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discern whether reduced TRPM3 has a role in reduced 
intracellular calcium ion concentration.
Conclusions
Our novel discovery of TRPM3 on NK and B lympho-
cytes and their significantly reduced expression in CFS/
ME patients, together with the preliminary discovery of 
impaired Ca2+ cytoplasmic concentration in these cells, 
suggests impaired Ca2+ metabolism may be implicated 
as a novel pathway for pathogenesis of CFS/ME. Further 
investigation may elucidate intracellular Ca2+ signalling 
pathways and the potential role this may play on tran-
scriptional factors, such as NFκB and NFAT as both are 
activated by calcium through the calmodulin dependent 
protein kinases and phosphatases. Moreover, as TRPs are 
widely expressed on almost all human cells and tissues, 
this raises the question as to whether similar changes of 
TRPM3 expression or function of these receptors pro-
motes more widespread disruption of intracellular signal-
ling homeostasis in CFS/ME patients.
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